chronic kidney disease
Conditions
Interventions
Tochu tea supplement (product name: Tochu gen GX) at recommended dose of 9 tablets per day is administered for 10 (8-12) weeks. Blood samples at the start and at the end of administration are used for
Sponsors
Dokkyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Chronic kidney disease patients at stages G1 to G3a (eGFR >45 mL/min/1.73m2) and/or proteinuria of more than 0.15g/gCr (or albuminuria of more than 30mg/gCr). 2. Males and females 20 years or more of age. 3. Those from whom consent to study participation was obtained with use of informed conset document.
Exclusion criteria
Exclusion criteria: 1. Those with malignant disease. 2. Those with dementia or impaired cognitive function. 3. Those with serious comorbid conditions who were judged not suited for participation by physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Circulating endothelial progenitor cell numbers by flowcytometry at the start and at the end of Tochu tea supplement administration for 10 (8-12) weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Circulating monocyte subset ratios (flowcytometry) , serum adiponectin, high-sensetivity CRP, oxidized LDL, oxidative stress (ROM) and anti-oxidative (BAP) indices, at the start and at the end of Tochu tea supplement administration for 10 (8-12) weeks. | — |
Countries
Japan
Contacts
Public ContactHiroshi Satonaka
Dokkyo Medical University Department of Nephrology and Hypertension
Outcome results
None listed